Cigna Research Reveals Less Than 1 in 3 Americans Have Strong Sense of Purpose
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy CI?
Source: PRnewswire
- Purpose and Health: Cigna's research indicates that individuals with a strong sense of purpose report significantly higher vitality, better health, stronger relationships, and greater work engagement; however, the 2025 Vitality in America report reveals that fewer than one in three American adults claim to have a strong sense of purpose.
- Social Impact: This finding highlights a widespread lack of purpose among American adults, which could adversely affect overall societal health and work efficiency, suggesting a need for businesses and policymakers to focus on enhancing mental health and sense of purpose.
- Research Background: The report is based on a comprehensive survey of American adults aimed at revealing the impact of purpose on personal quality of life, emphasizing the importance of mental health in modern society.
- Future Outlook: Cigna may leverage these findings to promote related health initiatives aimed at enhancing public sense of purpose and quality of life, thereby strengthening its competitive position in the health insurance market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 265.880
Low
300.00
Averages
335.63
High
378.00
Current: 265.880
Low
300.00
Averages
335.63
High
378.00
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CIGNA: Bernstein Upgrades to Outperform from Market Perform; Increases Target Price to $358 from $307
Company Performance: Cigna has reported an increase in market performance, indicating a positive trend in its financial health.
Target Price Adjustment: The target price for Cigna's stock has been raised to $358 from a previous $307, reflecting increased investor confidence.
See More
U.S. HMO Industry Faces Challenges and Opportunities
- Rising Medical Costs: U.S. health insurers are experiencing increased medical expenses due to the resumption of deferred care and heightened demand for chronic disease management, leading to a rise in insurance claims and pressure on profit margins.
- Regulatory Uncertainty: New legislation may tighten Medicaid eligibility and reduce ACA enrollment, impacting insurers' membership and reimbursements, which forces a shift towards commercial insurance products to enhance profitability.
- Healthcare Workforce Shortage: The ongoing shortage of nurses and healthcare professionals is straining hospital operations, affecting HMOs' ability to deliver high-quality care, which could lead to customer attrition.
- M&A Strategy: HMO companies are pursuing mergers and acquisitions to expand market share and enhance competitiveness, with expected interest rate declines in 2026 likely to fuel further M&A activity, driving industry consolidation.
See More
Challenging Stock Market Conditions, Yet These 5 Funds Are Thriving.
Positive Market News: Despite recent negative headlines regarding Iran, oil prices, market losses, and poor job numbers, there is encouraging news in the financial sector.
High-Performing Funds: Five investment funds are currently performing exceptionally well, providing a bright spot in an otherwise challenging economic landscape.
See More
Analysis of Current U.S. Labor Market Conditions
- Job Growth Expectations: February's nonfarm payrolls are projected to increase by approximately 60,000, down from 130,000 in January, indicating moderate growth in the labor market, though it fails to inspire strong economic confidence.
- Unemployment Rate Increase: The unemployment rate is expected to rise to 4.4% from 4.3% last month, reflecting signs of weakening consumer spending that could negatively impact economic growth.
- Weakening Consumer Spending: Real personal consumption expenditures have slowed to a year-over-year growth rate of 1.7%, about half of the long-term average, indicating a decline in consumer confidence that may affect future economic activity.
- Industry Dynamics Observation: While job growth in healthcare and social services continues, layoffs in the tech sector raise concerns, particularly regarding job shifts related to artificial intelligence, which may impact the overall structure of the labor market.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
Cigna Group's Financial Ratings Affirmed by AM Best
- Financial Strength Rating: AM Best has affirmed Cigna Group's Financial Strength Rating at A (Excellent) and Long-Term Issuer Credit Ratings at 'a+' (Excellent), reflecting its robust balance sheet and stable operating performance, which is expected to enhance investor confidence.
- Capital Adequacy Advantage: Cigna Life & Health Group's risk-adjusted capitalization is assessed at the highest level, and despite a financial leverage exceeding 43%, strong profitability and liquidity support its debt servicing capacity, ensuring future financial flexibility.
- Revenue Diversification: Cigna's revenue is geographically diversified, primarily from its commercial health insurance business in the U.S., and while the anticipated sale of its Medicare and CareAllies businesses in 2025 may decrease overall revenues, growth in cash flow is expected from its non-insurance operations through Evernorth Health Services.
- Mature Risk Management: Cigna has implemented a comprehensive Enterprise Risk Management (ERM) program that integrates risk management with strategic planning across business units, further enhancing the company's operational stability and market competitiveness.
See More
CIGNA: Bernstein Upgrades to Outperform from Market Perform; Increases Target Price to $358 from $307
Company Performance: Cigna has reported an increase in market performance, indicating a positive trend in its financial health.
Target Price Adjustment: The target price for Cigna's stock has been raised to $358 from a previous $307, reflecting increased investor confidence.
See More
U.S. HMO Industry Faces Challenges and Opportunities
- Rising Medical Costs: U.S. health insurers are experiencing increased medical expenses due to the resumption of deferred care and heightened demand for chronic disease management, leading to a rise in insurance claims and pressure on profit margins.
- Regulatory Uncertainty: New legislation may tighten Medicaid eligibility and reduce ACA enrollment, impacting insurers' membership and reimbursements, which forces a shift towards commercial insurance products to enhance profitability.
- Healthcare Workforce Shortage: The ongoing shortage of nurses and healthcare professionals is straining hospital operations, affecting HMOs' ability to deliver high-quality care, which could lead to customer attrition.
- M&A Strategy: HMO companies are pursuing mergers and acquisitions to expand market share and enhance competitiveness, with expected interest rate declines in 2026 likely to fuel further M&A activity, driving industry consolidation.
See More
Challenging Stock Market Conditions, Yet These 5 Funds Are Thriving.
Positive Market News: Despite recent negative headlines regarding Iran, oil prices, market losses, and poor job numbers, there is encouraging news in the financial sector.
High-Performing Funds: Five investment funds are currently performing exceptionally well, providing a bright spot in an otherwise challenging economic landscape.
See More
Analysis of Current U.S. Labor Market Conditions
- Job Growth Expectations: February's nonfarm payrolls are projected to increase by approximately 60,000, down from 130,000 in January, indicating moderate growth in the labor market, though it fails to inspire strong economic confidence.
- Unemployment Rate Increase: The unemployment rate is expected to rise to 4.4% from 4.3% last month, reflecting signs of weakening consumer spending that could negatively impact economic growth.
- Weakening Consumer Spending: Real personal consumption expenditures have slowed to a year-over-year growth rate of 1.7%, about half of the long-term average, indicating a decline in consumer confidence that may affect future economic activity.
- Industry Dynamics Observation: While job growth in healthcare and social services continues, layoffs in the tech sector raise concerns, particularly regarding job shifts related to artificial intelligence, which may impact the overall structure of the labor market.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
Cigna Group's Financial Ratings Affirmed by AM Best
- Financial Strength Rating: AM Best has affirmed Cigna Group's Financial Strength Rating at A (Excellent) and Long-Term Issuer Credit Ratings at 'a+' (Excellent), reflecting its robust balance sheet and stable operating performance, which is expected to enhance investor confidence.
- Capital Adequacy Advantage: Cigna Life & Health Group's risk-adjusted capitalization is assessed at the highest level, and despite a financial leverage exceeding 43%, strong profitability and liquidity support its debt servicing capacity, ensuring future financial flexibility.
- Revenue Diversification: Cigna's revenue is geographically diversified, primarily from its commercial health insurance business in the U.S., and while the anticipated sale of its Medicare and CareAllies businesses in 2025 may decrease overall revenues, growth in cash flow is expected from its non-insurance operations through Evernorth Health Services.
- Mature Risk Management: Cigna has implemented a comprehensive Enterprise Risk Management (ERM) program that integrates risk management with strategic planning across business units, further enhancing the company's operational stability and market competitiveness.
See More
